Publications by authors named "Daniel B Flora"
Article Synopsis
- This study investigates the impact of COVID-19 on female patients with breast cancer, particularly focusing on underrepresented racial/ethnic populations from March 2020 to June 2021 in the US.
- The analysis included 1,383 patients, revealing that older age and certain racial/ethnic groups (such as Black and Asian American/Pacific Islanders) showed higher odds of severe COVID-19 outcomes.
- Key findings noted that factors like worse performance status, pre-existing health conditions, and active cancer significantly contributed to increased severity, while variables like Hispanic ethnicity and anti-cancer therapy type did not impact outcomes as much.
Importance: Systematic data on the association between anticancer therapies and thromboembolic events (TEEs) in patients with COVID-19 are lacking.
Objective: To assess the association between anticancer therapy exposure within 3 months prior to COVID-19 and TEEs following COVID-19 diagnosis in patients with cancer.
Design, Setting, And Participants: This registry-based retrospective cohort study included patients who were hospitalized and had active cancer and laboratory-confirmed SARS-CoV-2 infection.
Article Synopsis
- A study examined outcomes of cancer patients who got COVID-19, focusing on those with and without existing cardiovascular disease (CVD) or risk factors (CVRF).
- The research found that over half of the 10,876 patients had CVD/CVRF, which linked to more severe COVID-19 symptoms and complications.
- Notably, patients without recent cancer treatment experienced worse COVID-19 severity related to CVD/CVRF compared to those under active treatment.
Article Synopsis
- The study investigates the impact of COVID-19 on female breast cancer patients using a large U.S. registry during 2020-2021, focusing on underrepresented racial/ethnic populations.
- Key findings show that older age, being Black, Asian American/Pacific Islander, and having worse overall health significantly increase the severity of COVID-19 in these patients.
- The overall hospitalization rate was 37% and mortality rate 9%, but these rates varied depending on the active status of breast cancer in patients.
Introduction: COVID-19 particularly impacted patients with co-morbid conditions, including cancer. Patients with melanoma have not been specifically studied in large numbers. Here, we sought to identify factors that associated with COVID-19 severity among patients with melanoma, particularly assessing outcomes of patients on active targeted or immune therapy.
View Article and Find Full Text PDFArticle Synopsis
- The COVID-19 pandemic has affected cancer patients differently across various regions in the U.S., showing that these patients are at a higher risk for severe COVID-19 complications.
- This study tracked and analyzed COVID-19 outcomes among cancer patients diagnosed between March and November 2020 across different U.S. census divisions, focusing on factors that may influence their health outcomes.
- Results indicated significant variability in 30-day mortality rates among cancer patients in different centers, ranging from 5.2% to 26.6%, suggesting that geographic location and healthcare center characteristics play a crucial role in these outcomes.
Article Synopsis
- A study investigated the impact of convalescent plasma treatment on 30-day mortality rates among hospitalized patients with hematologic cancers and COVID-19, as this group is known to have poor outcomes.
- The research utilized a retrospective cohort design, analyzing data from the COVID-19 and Cancer Consortium registry, focusing on patients admitted between March 2020 and January 2021.
- Results indicated that convalescent plasma treatment significantly improved 30-day mortality (HR, 0.60), with the benefit persisting even after accounting for potential confounding factors (HR, 0.52).